Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2005; 94(04): 892-894
DOI: 10.1055/s-0037-1615586
DOI: 10.1055/s-0037-1615586
Letters to the Editor
Pre-procedural levels of erythrocyte sedimentation rate (ESR) and risk of clinical restenosis in patients with percutaneous coronary intervention and coronary stent placement
Grant support:Monraats and Dr Agema are supported by grant 99.210 from the Netherlands Heart Foundation and a grant from the Interuniversity Cardiology Institute of the Netherlands (ICIN). Dr J. W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (2001 D 032).
Further Information
Publication History
Received25 March 2005
Accepted after revision18 July 2005
Publication Date:
11 December 2017 (online)
-
References
- 1 Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-8.
- 2 Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002; 39: 183-93.
- 3 Buffon A, Liuzzo G, Biasucci LM. et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-21.
- 4 Walter DH, Fichtlscherer S, Sellwig M. et al.. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-46.
- 5 Dibra A, Mehilli J, Braun S. et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003; 114: 715-22.
- 6 de Winter RJ, Koch KT, van Straalen JP. et al. C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med 2003; 115: 85-90.
- 7 Gomma AH, Hirschfield GM, Gallimore JR. Jr et al. Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J 2004; 147: 1071-7.
- 8 Saadeh C. The erythrocyte sedimentation rate: old and new clinical applications. South Med J 1998; 3: 220-5.
- 9 Brigden M. The erythrocyte sedimentation rate: still a helpful test when used judiciously. Postgrad Med 1998; 103: 257-74.
- 10 Sox Jr HC, Liang MH. The erythrocyte sedimentation rate: guidelines for rational use. Ann Intern Med 1986; 104: 515-23.
- 11 Stuart J, Whicher JT. Tests for detecting and monitoring the acute phase response. Arch Dis Child 1988; 63: 115-7.
- 12 Katz PR, Karuza J, Gutman SI. et al. A comparison between erythrocyte sedimentation rate (ESR) and selected acute-phase proteins in the elderly. Am J Clin Pathol 1990; 94: 637-40.
- 13 Andresdottir MB, Sigfusson N, Sigvaldason H. et al. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am J Epidemiol 2003; 158: 844-51.
- 14 Carlson LA, Bottiger LE, Ahfeldt PE. Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979; 206: 351-60.
- 15 Danesh J, Wheeler JG, Hirschfield GM. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
- 16 Gillum RF, Mussolino ME, Makuc DM. Erythrocyte sedimentation rate and coronary heart disease: the NHANES I Epidemiologic Follow-up Study. J Clin Epidemiol 1995; 48: 353-61.
- 17 Erikssen G, Liestol K, Bjornholt JV. et al. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J 2000; 21: 1614-20.
- 18 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237-46.
- 19 Rafnsson V, Bengtsson C. Erythrocyte sedimentation rate and cardiovascular disease. Results from a population study of women in Goteborg, Sweden. Atherosclerosis 1982; 42: 97-107.
- 20 Tibblin G, Wilhelmsen L, Werko L. Risk factors for myocardial infarction and death due to ischemic heart disease and other causes. Am J Cardiol 1975; 35: 514-22.
- 21 Danesh J, Collins R, Peto R. et al. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000; 21: 515-20.
- 22 Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004; 25: 1679-87.
- 23 Monraats PS, Rana JS, Zwinderman AH. et al. –455 G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost 2005; 93: 564-9.
- 24 Bhatt DL. Inflammation and restenosis: is there a link?. Am Heart J 2004; 147: 945-7.
- 25 Gottsauner-Wolf M, Zasmeta G, Hornykewycz S. et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000; 21: 1152-8.
- 26 Fukuda D, Shimada K, Tanaka A. et al. Circulating monocytes and instent neointima after coronary stent implantation. J Am Coll Cardiol 2004; 43: 18-23.
- 27 Hokimoto S, Ogawa H, Saito T. et al. Increased plasma antigen levels of monocyte chemoattractant protein-1 in patients with restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J 2000; 64: 831-4.
- 28 Schillinger M, Exner M, Mlekusch W. et al. Acutephase response after stent implantation in the carotid artery: association with 6-month instent restenosis. Radiology 2003; 227: 516-21.
- 29 Agema WRP, Monraats PS, Zwinderman AH. et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 2004; 25: 1163-70.
- 30 Garas SM, Huber P, Scott NA. Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol Ther 2001; 92: 165-78.